TABLE 2.
Effects of laninamivir octanoate and oseltamivir on clinical outcomea
| Parameter | Value for: |
||
|---|---|---|---|
| LOG 40 | LOG 20 | OG | |
| All eligible patients | |||
| n | 61 | 61 | 62 |
| Median time (h) to alleviation of influenza illness (95% CI) | 55.4 (46.3-81.3) | 56.4 (43.7-69.2) | 87.3 (67.9-129.7) |
| LOG 40 and LOG 20 vs OG | |||
| Median differenceb (h) (95% CI) | −31.9 (−43.4 to 0.5) | −31.0 (−50.3 to −5.5) | |
| P | 0.059 | 0.009 | |
| LOG 40 vs LOG 20 | |||
| Median differencec (h) (95% CI) | −1.0 (−9.0 to 22.4) | ||
| P | 0.372 | ||
| A/H1N1-infected patients | |||
| n | 40 | 40 | 32 |
| Median time (h) to alleviation of influenza illness (95% CI) | 49.6 (39.7-62.1) | 44.3 (24.3-58.9) | 110.5 (68.8-141.9) |
| Median differenceb (h) (95% CI) | −60.9 (−71.0 to −10.2) | −66.2 (−81.2 to −18.5) | |
| P | 0.007 | 0.001 | |
| A/H3N2-infected patients | |||
| n | 11 | 12 | 16 |
| Median time (h) to alleviation of influenza illness (95% CI) | 88.6 (43.5-114.9) | 70.4 (30.3-110.9) | 44.3 (22.9-82.1) |
| Median differenceb (h) (95% CI) | 44.4 (−14.8 to 68.5) | 26.2 (−24.8 to 51.2) | |
| P | 0.168 | 0.591 | |
| B-infected patients | |||
| n | 10 | 9 | 10 |
| Median time (h) to alleviation of influenza illness (95% CI) | 77.6 (51.8-95.8) | 83.5 (66.6-107.8) | 127.8 (77.1-165.3) |
| Median differenceb (h) (95% CI) | −50.2 (−104.4 to 10.4) | −44.3 (−93.8 to 36.1) | |
| P | 0.147 | 0.413 | |
a
Data are for the FAS. LOG 20 and LOG 40, groups given 20 and 40 mg of laninamivir octanoate, respectively; OG, oseltamivir group. Median times to alleviation of influenza illness were estimated by the Kaplan-Meier method. P values were determined by the generalized Wilcoxon test.
b
Median time to alleviation of influenza illness for the LOG 40 or LOG 20 − median time for the OG.
c
Median time to alleviation of influenza illness for the LOG 40 − median time for the LOG 20.